I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 78% ± 26% | |
| pancreatic A cell | 4 studies | 38% ± 12% | |
| endothelial cell of sinusoid | 3 studies | 26% ± 12% | |
| cholangiocyte | 3 studies | 53% ± 22% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 78% ± 26% | |
| pancreatic A cell | 4 studies | 38% ± 12% | |
| endothelial cell of sinusoid | 3 studies | 26% ± 12% | |
| cholangiocyte | 3 studies | 53% ± 22% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 66% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 152541.08 | 226 / 226 | 99% | 7489.18 | 401 / 406 |
| pancreas | 100% | 254.63 | 328 / 328 | 67% | 34.86 | 120 / 178 |
| lung | 83% | 128.10 | 478 / 578 | 30% | 13.39 | 350 / 1155 |
| kidney | 91% | 195.99 | 81 / 89 | 20% | 12.40 | 181 / 901 |
| stomach | 83% | 126.14 | 297 / 359 | 17% | 10.51 | 50 / 286 |
| ureter | 0% | 0 | 0 / 0 | 100% | 3.54 | 1 / 1 |
| intestine | 69% | 23.22 | 665 / 966 | 15% | 15.54 | 77 / 527 |
| peripheral blood | 40% | 324.91 | 375 / 929 | 0% | 0 | 0 / 0 |
| prostate | 27% | 6.27 | 66 / 245 | 12% | 1.88 | 59 / 502 |
| adrenal gland | 32% | 9.79 | 82 / 258 | 4% | 0.60 | 9 / 230 |
| spleen | 34% | 280.01 | 82 / 241 | 0% | 0 | 0 / 0 |
| uterus | 26% | 8.20 | 45 / 170 | 6% | 0.94 | 29 / 459 |
| esophagus | 23% | 8.20 | 337 / 1445 | 6% | 18.51 | 11 / 183 |
| ovary | 22% | 5.98 | 39 / 180 | 2% | 0.34 | 8 / 430 |
| thymus | 21% | 7.75 | 135 / 653 | 1% | 0.12 | 8 / 605 |
| bladder | 10% | 1.52 | 2 / 21 | 11% | 1.24 | 56 / 504 |
| skin | 14% | 7.33 | 256 / 1809 | 5% | 0.93 | 24 / 472 |
| heart | 19% | 10.63 | 163 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 17% | 6.93 | 223 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 16% | 29.22 | 196 / 1204 | 0% | 0 | 0 / 0 |
| breast | 14% | 11.39 | 64 / 459 | 1% | 0.61 | 11 / 1118 |
| brain | 11% | 3.63 | 289 / 2642 | 4% | 0.29 | 26 / 705 |
| muscle | 12% | 3.56 | 96 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.22 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| GO_0051917 | Biological process | regulation of fibrinolysis |
| GO_0051918 | Biological process | negative regulation of fibrinolysis |
| GO_0034197 | Biological process | triglyceride transport |
| GO_0033033 | Biological process | negative regulation of myeloid cell apoptotic process |
| GO_0034392 | Biological process | negative regulation of smooth muscle cell apoptotic process |
| GO_0016525 | Biological process | negative regulation of angiogenesis |
| GO_0001937 | Biological process | negative regulation of endothelial cell proliferation |
| GO_0006641 | Biological process | triglyceride metabolic process |
| GO_0030194 | Biological process | positive regulation of blood coagulation |
| GO_0051006 | Biological process | positive regulation of lipoprotein lipase activity |
| GO_0010596 | Biological process | negative regulation of endothelial cell migration |
| GO_0030195 | Biological process | negative regulation of blood coagulation |
| GO_0007597 | Biological process | blood coagulation, intrinsic pathway |
| GO_0031639 | Biological process | plasminogen activation |
| GO_0042627 | Cellular component | chylomicron |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0034364 | Cellular component | high-density lipoprotein particle |
| GO_0009986 | Cellular component | cell surface |
| GO_0034361 | Cellular component | very-low-density lipoprotein particle |
| GO_0031089 | Cellular component | platelet dense granule lumen |
| GO_0008201 | Molecular function | heparin binding |
| GO_0008289 | Molecular function | lipid binding |
| GO_0005543 | Molecular function | phospholipid binding |
| GO_0060230 | Molecular function | lipoprotein lipase activator activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | APOH |
| Protein name | Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Anticardiolipin cofactor) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI) Apolipoprotein H Beta-2-glycoprotein 1 (Apolipoprotein H) (Beta-2-glycoprotein I) |
| Synonyms | B2G1 hCG_1985715 |
| Description | FUNCTION: Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. FUNCTION: Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. . |
| Accessions | P02749 ENST00000581797.5 J3KS17 J3QLI0 ENST00000577982.1 ENST00000585162.1 J3QRN2 ENST00000205948.11 A0A384NKM6 |
